Georgina Arrambide
Overview
Explore the profile of Georgina Arrambide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
1674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marrodan M, Sao Aviles A, Rio J, Cobo-Calvo A, Fernandez V, Pappolla A, et al.
Mult Scler
. 2025 Feb;
:13524585251316471.
PMID: 39925147
Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and...
2.
Vilaseca A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, Arevalo M, Arino H, et al.
Mult Scler
. 2025 Feb;
:13524585251314749.
PMID: 39907218
Background: It is essential to exclude alternative diagnoses to diagnose multiple sclerosis (MS). However, detailed descriptions of alternative diagnoses in patients with suspected MS presenting with clinically isolated syndrome (CIS)...
3.
Cobo-Calvo A, Carbonell-Mirabent P, Tur C, Otero-Romero S, Carvajal R, Arrambide G, et al.
Neurology
. 2025 Feb;
104(4):e210305.
PMID: 39903901
Background And Objectives: Emerging concepts in the early detection of multiple sclerosis (MS) progression reveal that disability accumulation can start early in the disease course. Aging in MS is increasingly...
4.
Comabella M, Pappolla A, Monreal E, Fissolo N, Sao-Aviles A, Arrambide G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200370.
PMID: 39879564
Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP),...
5.
Villacieros-Alvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200362.
PMID: 39752619
Objectives: To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods: This...
6.
Villacieros-Alvarez J, Lunemann J, Sepulveda M, Valls-Carbo A, Dinoto A, Fernandez V, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Dec;
12(1):e200340.
PMID: 39661937
Background And Objectives: The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis...
7.
Carvajal R, Rodriguez-Acevedo B, Garcia-Vasco L, Zabalza A, Arino H, Bollo L, et al.
Mult Scler
. 2024 Nov;
30(14):1788-1801.
PMID: 39520297
Background: Organizing pneumonia (OP), an interstitial lung disease, has been observed in patients with inflammatory demyelinating diseases (IDDs) treated with anti-CD20, particularly after COVID-19, but data are limited. Aim: To...
8.
Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis
Arrambide G, Comabella M, Tur C
Front Immunol
. 2024 Nov;
15:1459502.
PMID: 39493759
Artificial intelligence (AI) has meant a turning point in data analysis, allowing predictions of unseen outcomes with precedented levels of accuracy. In multiple sclerosis (MS), a chronic inflammatory-demyelinating condition of...
9.
Prosperini L, Arrambide G, Celius E, Goletti D, Killestein J, Kos D, et al.
Lancet Reg Health Eur
. 2024 Oct;
44:100979.
PMID: 39429966
During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to the interaction between SARS-CoV-2, underlying neurological disease and the use of...
10.
Geraldes R, Arrambide G, Banwell B, Rovira A, Cortese R, Lassmann H, et al.
Nat Rev Neurol
. 2024 Sep;
20(10):620-635.
PMID: 39227463
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated demyelinating disease that is challenging to differentiate from multiple sclerosis (MS), as the clinical phenotypes overlap, and people with MOGAD...